Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Bausch & Lomb Corp (BLCO)

Bausch & Lomb Corp (BLCO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,028,563
  • Shares Outstanding, K 351,402
  • Annual Sales, $ 4,146 M
  • Annual Income, $ -260,000 K
  • 60-Month Beta 0.36
  • Price/Sales 1.19
  • Price/Cash Flow 7.49
  • Price/Book 0.73
Trade BLCO with:
  • Price/Earnings ttm 19.01
  • Earnings Per Share ttm 0.74
  • Most Recent Earnings $0.24 on 02/21/24
  • Latest Earnings Date 05/01/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    SIC-3851 Ophthalmic Goods

    Medical Services

Options Overview Details

View History
  • Implied Volatility 64.95% ( +9.44%)
  • Historical Volatility 30.26%
  • IV Percentile 97%
  • IV Rank 57.33%
  • IV High 107.01% on 09/15/23
  • IV Low 8.45% on 09/07/23
  • Put/Call Vol Ratio 0.33
  • Today's Volume 8
  • Volume Avg (30-Day) 346
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 10,403
  • Open Int (30-Day) 6,597

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 0.09
  • Number of Estimates 7
  • High Estimate 0.16
  • Low Estimate 0.03
  • Prior Year 0.10
  • Growth Rate Est. (year over year) -10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.80 +3.77%
on 04/12/24
17.52 -18.29%
on 03/28/24
-1.44 (-9.14%)
since 03/18/24
3-Month
13.62 +5.14%
on 02/05/24
17.69 -19.07%
on 02/23/24
-0.57 (-3.83%)
since 01/18/24
52-Week
13.62 +5.14%
on 02/05/24
21.95 -34.76%
on 06/30/23
-2.06 (-12.58%)
since 04/18/23

Most Recent Stories

More News
This Bausch Health Companies Unusually Active Option Is a No-Brainer

Bausch Health Companies had the 8th-highest Vol/OI ratio in Wednesday trading. The pharmaceutical company’s unusual options activity suggests it might have more gains ahead.

BHC : 8.60 (-0.69%)
BLCO : 14.32 (+0.07%)
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030

EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END

OKYO : 1.4653 (+3.92%)
ALC : 78.47 (-0.67%)
BLCO : 14.32 (+0.07%)
JNJ : 145.74 (+0.67%)
RHHBY : 30.0500 (-0.10%)
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030

/PRNewswire/ -- The Global Dry Eye Syndrome market has been growing substantially in the past years and is expected to continue through 2030. Dry Eye Syndrome...

OKYO : 1.4653 (+3.92%)
ALC : 78.47 (-0.67%)
BLCO : 14.32 (+0.07%)
JNJ : 145.74 (+0.67%)
RHHBY : 30.0500 (-0.10%)
Bausch + Lomb Announces First-Quarter 2023 Results and Provides 2023 Guidance

Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”, “we” or “our”), a leading global eye health company dedicated to helping people see better to live better,...

BLCO : 14.32 (+0.07%)
BLCO.TO : 19.66 (-0.96%)
Bausch + Lomb Releases Annual Environmental, Social and Governance Report

Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”, “we” or “our”), a leading global eye health company dedicated to helping people see better to live better,...

BLCO : 14.32 (+0.07%)
BLCO.TO : 19.66 (-0.96%)
Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 21 podium...

BLCO : 14.32 (+0.07%)
BLCO.TO : 19.66 (-0.96%)
Bausch + Lomb Announces 2023 Annual Meeting of Shareholder Results

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, today announced the election...

BLCO : 14.32 (+0.07%)
BLCO.TO : 19.66 (-0.96%)
Bausch + Lomb Announces U.S. Launch of StableVisc™ Cohesive Ophthalmic Viscosurgical Device and TotalVisc™ Viscoelastic System

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of StableVisc™...

BLCO : 14.32 (+0.07%)
BLCO.TO : 19.66 (-0.96%)
Bausch + Lomb Announces the Presentation of New Data on Products and Pipeline Programs at the Association for Research in Vision and Ophthalmology Meeting

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of eight scientific...

BLCO : 14.32 (+0.07%)
BLCO.TO : 19.66 (-0.96%)
Bausch + Lomb Reports More Than 65 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ONE by ONE and...

BLCO : 14.32 (+0.07%)
BLCO.TO : 19.66 (-0.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Bausch Lomb Corporation is an eye health company. Its product portfolio includes Biotrue(R) and renu(R) multi-purpose solutions, Biotrue(R) ONEday daily disposable contact lenses, LUMIFY(R) redness reliever eye drops, PreserVision(R) AREDS 2 formula eye vitamin and mineral supplements and VYZULTA(R)....

See More

Key Turning Points

3rd Resistance Point 15.31
2nd Resistance Point 15.02
1st Resistance Point 14.67
Last Price 14.32
1st Support Level 14.03
2nd Support Level 13.74
3rd Support Level 13.39

See More

52-Week High 21.95
Fibonacci 61.8% 18.77
Fibonacci 50% 17.78
Fibonacci 38.2% 16.80
Last Price 14.32
52-Week Low 13.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar